Spirepoint Private Client’s AbbVie ABBV Stock Holding History

Spirepoint Private Client’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.74M	Sell	26,767 -22,686	-46%	-$4.88M	0.55%	49
2026 Q1	$10.8M	Buy	49,453 +1,537	+3%	+$341K	1.02%	28
2025 Q4	$10.9M	Buy	47,916 +4,637	+11%	+$1.06M	1.05%	26
2025 Q3	$10M	Buy	43,279 +5,774	+15%	+$1.18M	1.05%	28
2025 Q2	$6.96M	Buy	37,505 +932	+3%	+$173K	0.79%	40
2025 Q1	$7.66M	Buy	36,573 +1,553	+4%	+$302K	1%	33
2024 Q4	$6.22M	Buy	35,020 +4,364	+14%	+$802K	0.78%	37
2024 Q3	$6.05M	Buy	30,656 +706	+2%	+$132K	0.8%	37
2024 Q2	$5.14M	Buy	29,950 +906	+3%	+$150K	0.73%	34
2024 Q1	$5.29M	Buy	+29,044	New	+$5.01M	0.81%	32

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Spirepoint Private Client's ABBV Position: Q2 2026 in Review

Spirepoint Private Client reduced its AbbVie (ABBV) stake by 46% in Q2 2026, selling an estimated $4.88M and leaving 26,767 shares worth $6.74M. The position accounts for 0.55% of the portfolio, ranked #49.

Spirepoint Private Client first reported a position in ABBV in Q1 2024 and has held it in 10 quarters since. The position peaked at $10.9M in Q4 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Spirepoint Private Client held 26,767 shares of AbbVie worth $6.74M as of Q2 2026.
Spirepoint Private Client sold 22,686 AbbVie shares in Q2 2026, an estimated $4.88M.
AbbVie made up 0.55% of Spirepoint Private Client's portfolio in Q2 2026, its #49 holding.
Spirepoint Private Client first reported a position in AbbVie in Q1 2024 and has held it in 10 quarters since.
Spirepoint Private Client's AbbVie position peaked at $10.9M in Q4 2025.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Spirepoint Private Client's 13F filing for Q2 2026, filed 5 Aug 2026.